Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT04945213

Biperiden Trial for Epilepsy Prevention

Led by Hospital Sirio-Libanes · Updated on 2024-03-26

312

Participants Needed

10

Research Sites

205 weeks

Total Duration

On this page

Sponsors

H

Hospital Sirio-Libanes

Lead Sponsor

P

PROADI-SUS

Collaborating Sponsor

AI-Summary

What this Trial Is About

One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.

CONDITIONS

Official Title

Biperiden Trial for Epilepsy Prevention

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Given informed consent
  • Between 18 and 75 years of age
  • Glasgow Coma Scale (GCS) between 6 and 12 at hospital admission, or between 3 and 5 if sedated with previous GCS between 6 and 15
  • Diagnosed with moderate or severe acute traumatic brain injury
  • All genders
  • Brain CT scan showing acute intraparenchymal hemorrhage and/or contusion
  • Able to receive the first dose of treatment or placebo within 18 hours of brain injury
Not Eligible

You will not qualify if you...

  • Previous use of biperiden
  • History of epilepsy confirmed by medical records
  • History of seizures or current use of antiepileptic medication
  • Pregnancy
  • Currently participating in another clinical trial
  • History of cancer, neurodegenerative diseases, stroke, cognitive impairment, benign prostatic hyperplasia, atrioventricular block or other cardiac arrhythmias, glaucoma, megacolon, or mechanical obstruction
  • Homelessness

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Instituto Doutor José Frota

Fortaleza, Ceará, Brazil

Not Yet Recruiting

2

Santa Casa de Misericórdia de Sobral

Sobral, Ceará, Brazil

Actively Recruiting

3

Hospital Estadual Urgencia e Emergencia -HEUE

Vitória, Espírito Santo, Brazil

Not Yet Recruiting

4

Hospital São Rafael

Salvador, Estado de Bahia, Brazil

Actively Recruiting

5

Associação Beneficente Santa Casa de Campo Grande

Campo Grande, Mato Grosso do Sul, Brazil

Actively Recruiting

6

Hospital São Vicente de Paulo

Passo Fundo, Rio Grande do Sul, Brazil

Active, Not Recruiting

7

Hospital das Clínicas da Faculdade de Medicina da Universidade de Ribeirão Preto

Ribeirão Preto, São Paulo, Brazil

Actively Recruiting

8

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

São Paulo, São Paulo, Brazil

Actively Recruiting

9

Hospital Sirio-Libanes

São Paulo, Brazil, 01308-000

Actively Recruiting

10

Hospital São Paulo, Universidade Federal de São Paulo

São Paulo, Brazil

Not Yet Recruiting

Loading map...

Research Team

E

Eliana Garzon, MD, PhD

CONTACT

M

Maira L Foresti, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here